|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Donohoe CL and Reynolds JV: Neoadjuvant
treatment of locally advanced esophageal and junctional cancer: The
evidence-base, current key questions and clinical trials. J Thorac
Dis. 9(Suppl 8): S697–S704. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schmidt B, Lee HJ, Ryeom S and Yoon SS:
Combining bevacizumab with radiation or chemoradiation for solid
tumors: A review of the scientific rationale, and clinical trials.
Curr Angiogenes. 1:169–179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Madden EC, Gorman AM, Logue SE and Samali
A: Tumour cell secretome in chemoresistance and tumour recurrence.
Trends Cancer. 6:489–505. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Smyth EC, Nilsson M, Grabsch HI, van
Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jia M, Qin D, Zhao C, Chai L, Yu Z, Wang
W, Tong L, Lv L, Wang Y, Rehwinkel J, et al: Redox homeostasis
maintained by GPX4 facilitates STING activation. Nat Immunol.
21:727–735. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou B, Liu J, Kang R, Klionsky DJ,
Kroemer G and Tang D: Ferroptosis is a type of autophagy-dependent
cell death. Semin Cancer Biol. 66:89–100. 2020. View Article : Google Scholar
|
|
9
|
Yang WS, SriRamaratnam R, Welsch ME,
Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji
AF, Clish CB, et al: Regulation of ferroptotic cancer cell death by
GPX4. Cell. 156:317–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu Y, Xie Y, Cao L, Yang L, Yang M, Lotze
MT, Zeh HJ, Kang R and Tang D: The ferroptosis inducer erastin
enhances sensitivity of acute myeloid leukemia cells to
chemotherapeutic agents. Mol Cell Oncol. 2:e10545492015. View Article : Google Scholar
|
|
11
|
Louandre C, Ezzoukhry Z, Godin C, Barbare
JC, Mazière JC, Chauffert B and Galmiche A: Iron-dependent cell
death of hepatocellular carcinoma cells exposed to sorafenib. Int J
Cancer. 133:1732–1742. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Louandre C, Marcq I, Bouhlal H, Lachaier
E, Godin C, Saidak Z, François C, Chatelain D, Debuysscher V,
Barbare JC, et al: The retinoblastoma (Rb) protein regulates
ferroptosis induced by sorafenib in human hepatocellular carcinoma
cells. Cancer Lett. 356:971–977. 2015. View Article : Google Scholar
|
|
13
|
Sun X, Niu X, Chen R, He W, Chen D, Kang R
and Tang D: Metallothionein-1G facilitates sorafenib resistance
through inhibition of ferroptosis. Hepatology. 64:488–500. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R
and Tang D: Activation of the p62-Keap1-NRF2 pathway protects
against ferroptosis in hepatocellular carcinoma cells. Hepatology.
63:173–184. 2016. View Article : Google Scholar
|
|
15
|
Eling N, Reuter L, Hazin J, Hamacher-Brady
A and Brady NR: Identification of artesunate as a specific
activator of ferroptosis in pancreatic cancer cells. Oncoscience.
2:517–532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu S, Zhang Q, Sun X, Zeh HJ III, Lotze
MT, Kang R and Tang D: HSPA5 regulates ferroptotic cell death in
cancer cells. Cancer Res. 77:2064–2077. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Berger SL, Kouzarides T, Shiekhattar R and
Shilatifard A: An operational definition of epigenetics. Genes Dev.
23:781–783. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Holliday R: The inheritance of epigenetic
defects. Science. 238:163–170. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou S, Liu J, Wan A, Zhang Y and Qi X:
Epigenetic regulation of diverse cell death modalities in cancer: a
focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis.
J Hematol Oncol. 17:222024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stockwell BR, Friedmann Angeli JP, Bayir
H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK,
Kagan VE, et al: Ferroptosis: A regulated cell death nexus linking
metabolism, redox biology, and disease. Cell. 171:273–285. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kuang F, Liu J, Tang D and Kang R:
Oxidative damage and antioxidant defense in ferroptosis. Front Cell
Dev Biol. 8:5865782020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Torti SV and Torti FM: Iron and cancer:
More ore to be mined. Nat Rev Cancer. 13:342–355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hassannia B, Vandenabeele P and Vanden
Berghe T: Targeting ferroptosis to iron out cancer. Cancer Cell.
35:830–849. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang WS, Kim KJ, Gaschler MM, Patel M,
Shchepinov MS and Stockwell BR: Peroxidation of polyunsaturated
fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci
USA. 113:E4966–E4975. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Suttner DM and Dennery PA: Reversal of
HO-1 related cytoprotection with increased expression is due to
reactive iron. FASEB J. 13:1800–1809. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang WS and Stockwell BR: Synthetic lethal
screening identifies compounds activating Iron-dependent,
nonapoptotic cell death in oncogenic-RAS-harboring cancer cells.
Chem Biol. 15:234–245. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang Y, Liu Y, Liu J, Kang R and Tang D:
NEDD4L-mediated LTF protein degradation limits ferroptosis. Biochem
Biophys Res Commun. 531:581–587. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Drakesmith H, Nemeth E and Ganz T: Ironing
out Ferroportin. Cell Metab. 22:777–787. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Donovan A, Lima CA, Pinkus JL, Pinkus GS,
Zon LI, Robine S and Andrews NC: The iron exporter
ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab.
1:191–200. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Donovan A, Brownlie A, Zhou Y, Shepard J,
Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, et al:
Positional cloning of zebrafish ferroportin1 identifies a conserved
vertebrate iron exporter. Nature. 403:776–781. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nemeth E, Tuttle MS, Powelson J, Vaughn
MB, Donovan A, Ward DM, Ganz T and Kaplan J: Hepcidin regulates
cellular iron efflux by binding to ferroportin and inducing its
internalization. Science. 306:2090–2093. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
De Domenico I, Ward DM, Langelier C,
Vaughn MB, Nemeth E, Sundquist WI, Ganz T, Musci G and Kaplan J:
The molecular mechanism of hepcidin-mediated ferroportin
down-regulation. Mol Biol Cell. 18:2569–2578. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qiao B, Sugianto P, Fung E,
Del-Castillo-Rueda A, Moran-Jimenez MJ, Ganz T and Nemeth E:
Hepcidin-induced endocytosis of ferroportin is dependent on
ferroportin ubiquitination. Cell Metab. 15:918–924. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ross SL, Tran L, Winters A, Lee KJ, Plewa
C, Foltz I, King C, Miranda LP, Allen J, Beckman H, et al:
Molecular mechanism of hepcidin-mediated ferroportin
internalization requires ferroportin lysines, not tyrosines or
JAK-STAT. Cell Metab. 15:905–917. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Geng N, Shi BJ, Li SL, Zhong ZY, Li YC,
Xua WL, Zhou H and Cai JH: Knockdown of ferroportin accelerates
erastin-induced ferroptosis in neuroblastoma cells. Eur Rev Med
Pharmacol Sci. 22:3826–3836. 2018.PubMed/NCBI
|
|
36
|
Tang Z, Jiang W, Mao M, Zhao J, Chen J and
Cheng N: Deubiquitinase USP35 modulates ferroptosis in lung cancer
via targeting ferroportin. Clin Transl Med. 11:e3902021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gao M, Monian P, Pan Q, Zhang W, Xiang J
and Jiang X: Ferroptosis is an autophagic cell death process. Cell
Res. 26:1021–1032. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh
HJ III, Kang R and Tang D: Autophagy promotes ferroptosis by
degradation of ferritin. Autophagy. 12:1425–1428. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mancias JD, Wang X, Gygi SP, Harper JW and
Kimmelman AC: Quantitative proteomics identifies NCOA4 as the cargo
receptor mediating ferritinophagy. Nature. 509:105–109. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang YQ, Chang SY, Wu Q, Gou YJ, Jia L,
Cui YM, Yu P, Shi ZH, Wu WS, Gao G and Chang YZ: The Protective
role of mitochondrial ferritin on Erastin-induced ferroptosis.
Front Aging Neurosci. 8:3082016. View Article : Google Scholar
|
|
41
|
Torii S, Shintoku R, Kubota C, Yaegashi M,
Torii R, Sasaki M, Suzuki T, Mori M, Yoshimoto Y, Takeuchi T and
Yamada K: An essential role for functional lysosomes in ferroptosis
of cancer cells. Biochem J. 473:769–777. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fang Y, Chen X, Tan Q, Zhou H, Xu J and Gu
Q: Inhibiting ferroptosis through disrupting the NCOA4-FTH1
interaction: A new mechanism of action. ACS Cent Sci. 7:980–989.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen PH, Wu J, Ding CC, Lin CC, Pan S,
Bossa N, Xu Y, Yang WH, Mathey-Prevot B and Chi JT: Kinome screen
of ferroptosis reveals a novel role of ATM in regulating iron
metabolism. Cell Death Differ. 27:1008–1022. 2020. View Article : Google Scholar :
|
|
44
|
Kagan VE, Mao G, Qu F, Angeli JP, Doll S,
Croix CS, Dar HH, Liu B, Tyurin VA, Ritov VB, et al: Oxidized
arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem
Biol. 13:81–90. 2017. View Article : Google Scholar
|
|
45
|
Doll S, Proneth B, Tyurina YY, Panzilius
E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A,
et al: ACSL4 dictates ferroptosis sensitivity by shaping cellular
lipid composition. Nat Chem Biol. 13:91–98. 2017. View Article : Google Scholar :
|
|
46
|
Yuan H, Li X, Zhang X, Kang R and Tang D:
Identification of ACSL4 as a biomarker and contributor of
ferroptosis. Biochem Biophys Res Commun. 478:1338–1343. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dixon SJ, Winter GE, Musavi LS, Lee ED,
Snijder B, Rebsamen M, Superti-Furga G and Stockwell BR: Human
haploid cell genetics reveals roles for lipid metabolism genes in
nonapoptotic cell death. ACS Chem Biol. 10:1604–1609. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Conrad M and Pratt DA: The chemical basis
of ferroptosis. Nat Chem Biol. 15:1137–1147. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yin H, Xu L and Porter NA: Free radical
lipid peroxidation: Mechanisms and analysis. Chem Rev.
111:5944–5972. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Doll S, Freitas FP, Shah R, Aldrovandi M,
da Silva MC, Ingold I, Goya Grocin A, Xavier da Silva TN, Panzilius
E, Scheel CH, et al: FSP1 is a glutathione-independent ferroptosis
suppressor. Nature. 575:693–698. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bersuker K, Hendricks JM, Li Z, Magtanong
L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, et al:
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit
ferroptosis. Nature. 575:688–692. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ayala A, Muñoz MF and Argüelles S: Lipid
peroxidation: Production, metabolism, and signaling mechanisms of
malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev.
2014:3604382014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fenton HJH: LXXIII.-Oxidation of tartaric
acid in presence of iron. J Chemical Soc Transactions. 65:899–910.
1894. View Article : Google Scholar
|
|
54
|
Haeggström JZ and Funk CD: Lipoxygenase
and leukotriene pathways: Biochemistry, biology, and roles in
disease. Chem Rev. 111:5866–5898. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Li Y, Maher P and Schubert D: A role for
12-lipoxygenase in nerve cell death caused by glutathione
depletion. Neuron. 19:453–463. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Seiler A, Schneider M, Förster H, Roth S,
Wirth EK, Culmsee C, Plesnila N, Kremmer E, Rådmark O, Wurst W, et
al: Glutathione peroxidase 4 senses and translates oxidative stress
into 12/15-lipoxygenase dependent- and AIF-mediated cell death.
Cell Metab. 8:237–248. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Brütsch SH, Wang CC, Li L, Stender H,
Neziroglu N, Richter C, Kuhn H and Borchert A: Expression of
inactive glutathione peroxidase 4 leads to embryonic lethality, and
inactivation of the Alox15 gene does not rescue such knock-in mice.
Antioxid Redox Signal. 22:281–293. 2015. View Article : Google Scholar
|
|
58
|
Jiang X, Stockwell BR and Conrad M:
Ferroptosis: Mechanisms, biology and role in disease. Nat Rev Mol
Cell Biol. 22:266–282. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chu B, Kon N, Chen D, Li T, Liu T, Jiang
L, Song S, Tavana O and Gu W: ALOX12 is required for p53-mediated
tumour suppression through a distinct ferroptosis pathway. Nat Cell
Biol. 21:579–591. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zou Y, Li H, Graham ET, Deik AA, Eaton JK,
Wang W, Sandoval-Gomez G, Clish CB, Doench JG and Schreiber SL:
Cytochrome P450 oxidoreductase contributes to phospholipid
peroxidation in ferroptosis. Nat Chem Biol. 16:302–309. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Xie Y, Kang R, Klionsky DJ and Tang D:
GPX4 in cell death, autophagy, and disease. Autophagy.
19:2621–2638. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yant LJ, Ran Q, Rao L, Van Remmen H,
Shibatani T, Belter JG, Motta L, Richardson A and Prolla TA: The
selenoprotein GPX4 is essential for mouse development and protects
from radiation and oxidative damage insults. Free Radic Biol Med.
34:496–502. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Brigelius-Flohé R and Maiorino M:
Glutathione peroxidases. Biochim Biophys Acta. 1830:3289–3303.
2013. View Article : Google Scholar
|
|
64
|
Meister A: Glutathione metabolism. Methods
Enzymol. 251:3–7. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lu SC: Regulation of glutathione
synthesis. Mol Aspects Med. 30:42–59. 2009. View Article : Google Scholar :
|
|
66
|
Cao JY and Dixon SJ: Mechanisms of
ferroptosis. Cell Mol Life Sci. 73:2195–2209. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sato H, Tamba M, Ishii T and Bannai S:
Cloning and expression of a plasma membrane cystine/glutamate
exchange transporter composed of two distinct proteins. J Biol
Chem. 274:11455–11458. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Sato H, Shiiya A, Kimata M, Maebara K,
Tamba M, Sakakura Y, Makino N, Sugiyama F, Yagami K, Moriguchi T,
et al: Redox imbalance in cystine/glutamate transporter-deficient
mice. J Biol Chem. 280:37423–37429. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Friedmann Angeli JP, Schneider M, Proneth
B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch
A, Eggenhofer E, et al: Inactivation of the ferroptosis regulator
Gpx4 triggers acute renal failure in mice. Nat Cell Biol.
16:1180–1191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Chen D, Tavana O, Chu B, Erber L, Chen Y,
Baer R and Gu W: NRF2 is a major target of ARF in p53-independent
tumor suppression. Mol Cell. 68:224–232.e4. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Jiang L, Kon N, Li T, Wang SJ, Su T,
Hibshoosh H, Baer R and Gu W: Ferroptosis as a p53-mediated
activity during tumour suppression. Nature. 520:57–62. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhang Y, Shi J, Liu X, Feng L, Gong Z,
Koppula P, Sirohi K, Li X, Wei Y, Lee H, et al: BAP1 links
metabolic regulation of ferroptosis to tumour suppression. Nat Cell
Biol. 20:1181–1192. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Song X, Zhu S, Chen P, Hou W, Wen Q, Liu
J, Xie Y, Liu J, Klionsky DJ, Kroemer G, et al: AMPK-mediated BECN1
phosphorylation promotes ferroptosis by directly blocking system
Xc-activity. Curr Biol. 28:2388–2399.e5. 2018. View Article : Google Scholar
|
|
74
|
Yang M, Tsui MG, Tsang JKW, Goit RK, Yao
KM, So KF, Lam WC and Lo ACY: Involvement of FSP1-CoQ(10)-NADH and
GSH-GPx-4 pathways in retinal pigment epithelium ferroptosis. Cell
Death Dis. 13:4682022. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zeng F, Chen X and Deng G: The
anti-ferroptotic role of FSP1: Current molecular mechanism and
therapeutic approach. Mol Biomed. 3:372022. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Kraft VAN, Bezjian CT, Pfeiffer S,
Ringelstetter L, Müller C, Zandkarimi F, Merl-Pham J, Bao X,
Anastasov N, Kössl J, et al: GTP Cyclohydrolase
1/Tetrahydrobiopterin counteract ferroptosis through lipid
remodeling. ACS Cent Sci. 6:41–53. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Cheng Y, He C, Wang M, Ma X, Mo F, Yang S,
Han J and Wei X: Targeting epigenetic regulators for cancer
therapy: Mechanisms and advances in clinical trials. Signal
Transduct Target Ther. 4:622019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Logie E, Van Puyvelde B, Cuypers B,
Schepers A, Berghmans H, Verdonck J, Laukens K, Godderis L,
Dhaenens M, Deforce D, et al: Ferroptosis induction in multiple
myeloma cells triggers DNA methylation and histone modification
changes associated with cellular senescence. Int J Mol Sci.
22:122342021. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Bird A: DNA methylation patterns and
epigenetic memory. Genes Dev. 16:6–21. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Parry A, Rulands S and Reik W: Active
turnover of DNA methylation during cell fate decisions. Nat Rev
Genet. 22:59–66. 2021. View Article : Google Scholar
|
|
81
|
Tahiliani M, Koh KP, Shen Y, Pastor WA,
Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, et
al: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in
mammalian DNA by MLL partner TET1. Science. 324:930–935. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ito S, D'Alessio AC, Taranova OV, Hong K,
Sowers LC and Zhang Y: Role of Tet proteins in 5mC to 5hmC
conversion, ES-cell self-renewal and inner cell mass specification.
Nature. 466:1129–1133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Ito S, Shen L, Dai Q, Wu SC, Collins LB,
Swenberg JA, He C and Zhang Y: Tet proteins can convert
5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine.
Science. 333:1300–1303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Robertson KD: DNA methylation and human
disease. Nat Rev Genet. 6:597–610. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Esteller M: Epigenetic gene silencing in
cancer: The DNA hypermethylome. Hum Mol Genet. 16(Spec No 1):
R50–R59. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Veigl ML, Kasturi L, Olechnowicz J, Ma AH,
Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL,
Sedwick WD, et al: Biallelic inactivation of hMLH1 by epigenetic
gene silencing, a novel mechanism causing human MSI cancers. Proc
Natl Acad Sci USA. 95:8698–8702. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Klutstein M, Nejman D, Greenfield R and
Cedar H: DNA methylation in cancer and aging. Cancer Res.
76:3446–3450. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Liu Z, Zhao Q, Zuo ZX, Yuan SQ, Yu K,
Zhang Q, Zhang X, Sheng H, Ju HQ, Cheng H, et al: Systematic
analysis of the aberrances and functional implications of
ferroptosis in cancer. iScience. 23:1013022020. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Lee JY, Nam M, Son HY, Hyun K, Jang SY,
Kim JW, Kim MW, Jung Y, Jang E, Yoon SJ, et al: Polyunsaturated
fatty acid biosynthesis pathway determines ferroptosis sensitivity
in gastric cancer. Proc Natl Acad Sci USA. 117:32433–32442. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Liu Y, Ouyang L, Mao C, Chen Y, Li T, Liu
N, Wang Z, Lai W, Zhou Y, Cao Y, et al: PCDHB14 promotes
ferroptosis and is a novel tumor suppressor in hepatocellular
carcinoma. Oncogene. 41:3570–3583. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Bolotta A, Abruzzo PM, Baldassarro VA,
Ghezzo A, Scotlandi K, Marini M and Zucchini C: New insights into
the Hepcidin-ferroportin axis and iron homeostasis in iPSC-derived
cardiomyocytes from Friedreich's ataxia patient. Oxid Med Cell
Longev. 2019:76230232019. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Udali S, Castagna A, Corbella M,
Ruzzenente A, Moruzzi S, Mazzi F, Campagnaro T, De Santis D,
Franceschi A, Pattini P, et al: Hepcidin and DNA promoter
methylation in hepatocellular carcinoma. Eur J Clin Invest.
48:e128702018. View Article : Google Scholar
|
|
93
|
Udali S, Guarini P, Ruzzenente A,
Ferrarini A, Guglielmi A, Lotto V, Tononi P, Pattini P, Moruzzi S,
Campagnaro T, et al: DNA methylation and gene expression profiles
show novel regulatory pathways in hepatocellular carcinoma. Clin
Epigenetics. 7:432015. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Cai C, Zhu Y, Mu J, Liu S, Yang Z, Wu Z,
Zhao C, Song X, Ye Y, Gu J, et al: DNA methylation of RUNX3
promotes the progression of gallbladder cancer through repressing
SLC7A11-mediated ferroptosis. Cell Signal. 108:1107102023.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Cedar H and Bergman Y: Linking DNA
methylation and histone modification: Patterns and paradigms. Nat
Rev Genet. 10:295–304. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Du Q, Luu PL, Stirzaker C and Clark SJ:
Methyl-CpG-binding domain proteins: Readers of the epigenome.
Epigenomics. 7:1051–1073. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Shimazu T, Hirschey MD, Newman J, He W,
Shirakawa K, Le Moan N, Grueter CA, Lim H, Saunders LR, Stevens RD,
et al: Suppression of oxidative stress by β-hydroxybutyrate, an
endogenous histone deacetylase inhibitor. Science. 339:211–214.
2013. View Article : Google Scholar
|
|
98
|
Cui X, Yun X, Sun M, Li R, Lyu X, Lao Y,
Qin X and Yu W: HMGCL-induced β-hydroxybutyrate production
attenuates hepatocellular carcinoma via DPP4-mediated ferroptosis
susceptibility. Hepatol Int. 17:377–392. 2023. View Article : Google Scholar
|
|
99
|
Li Y, Hu G, Huang F, Chen M, Chen Y, Xu Y
and Tong G: MAT1A suppression by the CTBP1/HDAC1/HDAC2
transcriptional complex induces immune escape and reduces
ferroptosis in hepatocellular carcinoma. Lab Invest.
103:1001802023. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Xue X, Ma L, Zhang X, Xu X, Guo S, Wang Y,
Qiu S, Cui J, Guo W, Yu Y, et al: Tumour cells are sensitised to
ferroptosis via RB1CC1-mediated transcriptional reprogramming. Clin
Transl Med. 12:e7472022. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Ma M, Kong P, Huang Y, Wang J, Liu X, Hu
Y, Chen X, Du C and Yang H: Activation of MAT2A-ACSL3 pathway
protects cells from ferroptosis in gastric cancer. Free Radic Biol
Med. 181:288–299. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Jiang K, Yin X, Zhang Q, Yin J, Tang Q, Xu
M, Wu L, Shen Y, Zhou Z, Yu H, et al: STC2 activates PRMT5 to
induce radioresistance through DNA damage repair and ferroptosis
pathways in esophageal squamous cell carcinoma. Redox Biol.
60:1026262023. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Wang Y, Yang L, Zhang X, Cui W, Liu Y, Sun
QR, He Q, Zhao S, Zhang GA, Wang Y, et al: Epigenetic regulation of
ferroptosis by H2B monoubiquitination and p53. EMBO Rep.
20:e475632019. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Quinn JJ and Chang HY: Unique features of
long non-coding RNA biogenesis and function. Nat Rev Genet.
17:47–62. 2016. View Article : Google Scholar
|
|
105
|
Guttman M and Rinn JL: Modular regulatory
principles of large Non-coding RNAs. Nature. 482:339–346. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Ni H, Qin H, Sun C, Liu Y, Ruan G, Guo Q,
Xi T, Xing Y and Zheng L: MiR-375 reduces the stemness of gastric
cancer cells through triggering ferroptosis. Stem Cell Res Ther.
12:3252021. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Mao SH, Zhu CH, Nie Y, Yu J and Wang L:
Levobupivacaine Induces Ferroptosis by miR-489-3p/SLC7A11 Signaling
in Gastric Cancer. Front Pharmacol. 12:6813382021. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Dong X, Chen X, Zhao Y, Wu Q and Ren Y:
CircTMEM87A promotes the tumorigenesis of gastric cancer by
regulating the miR-1276/SLC7A11 axis. J Gastroenterol Hepatol.
39:121–132. 2024. View Article : Google Scholar
|
|
109
|
Martino E, Balestrieri A, Aragona F,
Bifulco G, Mele L, Campanile G, Balestrieri ML and D'Onofrio N:
MiR-148a-3p promotes colorectal cancer cell ferroptosis by
targeting SLC7A11. Cancers (Basel). 15:43422023. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Elrebehy MA, Abdelghany TM, Elshafey MM,
Gomaa MH and Doghish AS: miR-509-5p promotes colorectal cancer cell
ferroptosis by targeting SLC7A11. Pathol Res Pract. 247:1545572023.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Liu L, Yao H, Zhou X, Chen J, Chen G, Shi
X, Wu G, Zhou G and He S: MiR-15a-3p regulates ferroptosis via
targeting glutathione peroxidase GPX4 in colorectal cancer. Mol
Carcinog. 61:301–310. 2022. View Article : Google Scholar
|
|
112
|
He GN, Bao NR, Wang S, Xi M, Zhang TH and
Chen FS: Ketamine induces ferroptosis of liver cancer cells by
Targeting lncRNA PVT1/miR-214-3p/GPX4. Drug Des Devel Ther.
15:3965–3978. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Yang Y, Lin Z, Han Z, Wu Z, Hua J, Zhong
R, Zhao R, Ran H, Qu K, Huang H, et al: miR-539 activates the
SAPK/JNK signaling pathway to promote ferropotosis in colorectal
cancer by directly targeting TIPE. Cell Death Discov. 7:2722021.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Dodson M, Castro-Portuguez R and Zhang DD:
NRF2 plays a critical role in mitigating lipid peroxidation and
ferroptosis. Redox Biol. 23:1011072019. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Zheng F, Bi JC, Wei YY, Wang Y, Zhang Q,
Liang CL, Wu J and Dai Z: MiR-124-3p mediates gastric cancer cell
ferroptosis induced by an anti-cancer drug polyphyllin I. Front
Pharmacol. 14:12857992023. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Yamamoto S, Inoue J, Kawano T, Kozaki K,
Omura K and Inazawa J: The impact of miRNA-based molecular
diagnostics and treatment of NRF2-stabilized tumors. Mol Cancer
Res. 12:58–68. 2014. View Article : Google Scholar
|
|
117
|
Xiao S, Liu N, Yang X, Ji G and Li M:
Polygalacin D suppresses esophageal squamous cell carcinoma growth
and metastasis through regulating miR-142-5p/Nrf2 axis. Free Radic
Biol Med. 164:58–75. 2021. View Article : Google Scholar
|
|
118
|
Akdemir B, Nakajima Y, Inazawa J and Inoue
J: miR-432 Induces NRF2 stabilization by directly targeting KEAP1.
Mol Cancer Res. 15:1570–1578. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Liu M, Hu C, Xu Q, Chen L, Ma K, Xu N and
Zhu H: Methylseleninic acid activates Keap1/Nrf2 pathway via
up-regulating miR-200a in human oesophageal squamous cell carcinoma
cells. Biosci Rep. 35:e002562015. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Li P, Liu X, Xing W, Qiu H, Li R, Liu S
and Sun H: Exosome-derived miR-200a promotes esophageal cancer cell
proliferation and migration via the mediating Keap1 expression. Mol
Cell Biochem. 477:1295–1308. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Shi L, Wu L, Chen Z, Yang J, Chen X, Yu F,
Zheng F and Lin X: MiR-141 activates Nrf2-dependent antioxidant
pathway via Down-regulating the expression of keap1 conferring the
resistance of hepatocellular carcinoma cells to 5-Fluorouracil.
Cell Physiol Biochem. 35:2333–2348. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Xiao Z, Zheng YB, Dao WX, Luo JF, Deng WH,
Yan RC and Liu JS: MicroRNA-328-3p facilitates the progression of
gastric cancer via KEAP1/NRF2 axis. Free Radic Res. 55:720–730.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Lewerenz J and Maher P: Basal levels of
eIF2alpha phosphorylation determine cellular antioxidant status by
regulating ATF4 and xCT expression. J Biol Chem. 284:1106–1115.
2009. View Article : Google Scholar :
|
|
124
|
He F, Zhang P, Liu J, Wang R, Kaufman RJ,
Yaden BC and Karin M: ATF4 suppresses hepatocarcinogenesis by
inducing SLC7A11 (xCT) to block stress-related ferroptosis. J
Hepatol. 79:362–377. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Bai T, Liang R, Zhu R, Wang W, Zhou L and
Sun Y: MicroRNA-214-3p enhances Erastin-induced ferroptosis by
targeting ATF4 in hepatoma cells. J Cell Physiol. 235:5637–5648.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Yang H, Sun W, Bi T, Sun J, Lu Z, Li J and
Wei H: ZNF8-miR-552-5p axis modulates ACSL4-Mediated ferroptosis in
hepatocellular carcinoma. DNA Cell Biol. 42:336–347. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Lu Y, Chan YT, Tan HY, Zhang C, Guo W, Xu
Y, Sharma R, Chen ZS, Zheng YC, Wang N, et al: Epigenetic
regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates
sorafenib resistance in human hepatocellular carcinoma. J Exp Clin
Cancer Res. 41:32022. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Qi R, Bai Y, Li K, Liu N, Xu Y, Dal E,
Wang Y, Lin R, Wang H, Liu Z, et al: Cancer-associated fibroblasts
suppress ferroptosis and induce gemcitabine resistance in
pancreatic cancer cells by secreting exosome-derived
ACSL4-targeting miRNAs. Drug Resist Updat. 68:1009602023.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Wang W, Wang T, Zhang Y, Deng T, Zhang H
and Ba YI: Gastric cancer secreted miR-214-3p inhibits the
anti-angiogenesis effect of apatinib by suppressing ferroptosis in
vascular endothelial cells. Oncol Res. 32:489–502. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Xing K, Bian X, Shi D, Dong S, Zhou H,
Xiao S, Bai J and Wu W: miR-612 Enhances RSL3-induced ferroptosis
of hepatocellular carcinoma cells via mevalonate pathway. J
Hepatocell Carcinoma. 10:2173–2185. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Yang WS and Stockwell BR: Ferroptosis:
Death by lipid peroxidation. Trends Cell Biol. 26:165–176. 2016.
View Article : Google Scholar :
|
|
132
|
Zhang H, Deng T, Liu R, Ning T, Yang H,
Liu D, Zhang Q, Lin D, Ge S, Bai M, et al: CAF secreted miR-522
suppresses ferroptosis and promotes acquired chemo-resistance in
gastric cancer. Mol Cancer. 19:432020. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Zheng S, Hu L, Song Q, Shan Y, Yin G, Zhu
H, Kong W and Zhou C: miR-545 promotes colorectal cancer by
inhibiting transferring in the non-normal ferroptosis signaling.
Aging (Albany NY). 13:26137–26147. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Hamara K, Bielecka-Kowalska A,
Przybylowska-Sygut K, Sygut A, Dziki A and Szemraj J: Alterations
in expression profile of iron-related genes in colorectal cancer.
Mol Biol Rep. 40:5573–5585. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Greene CM, Varley RB and Lawless MW:
MicroRNAs and liver cancer associated with iron overload:
Therapeutic targets unravelled. World J Gastroenterol.
19:5212–5226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Kindrat I, Tryndyak V, de Conti A,
Shpyleva S, Mudalige TK, Kobets T, Erstenyuk AM, Beland FA and
Pogribny IP: MicroRNA-152-mediated dysregulation of hepatic
transferrin receptor 1 in liver carcinogenesis. Oncotarget.
7:1276–1287. 2016. View Article : Google Scholar :
|
|
137
|
Galy B, Conrad M and Muckenthaler M:
Mechanisms controlling cellular and systemic iron homeostasis. Nat
Rev Mol Cell Biol. 25:133–155. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Sangokoya C, Doss JF and Chi JT:
Iron-responsive miR-485-3p regulates cellular iron homeostasis by
targeting ferroportin. PLoS Genet. 9:e10034082013. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Fan H, Ai R, Mu S, Niu X, Guo Z and Liu L:
MiR-19a suppresses ferroptosis of colorectal cancer cells by
targeting IREB2. Bioengineered. 13:12021–12029. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Balihodzic A, Prinz F, Dengler MA, Calin
GA, Jost PJ and Pichler M: Non-coding RNAs and ferroptosis:
Potential implications for cancer therapy. Cell Death Differ.
29:1094–1106. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Wu C, Hou X, Li S and Luo S: Long
noncoding RNA ZEB1-AS1 attenuates ferroptosis of gastric cancer
cells through modulating miR-429/BGN axis. J Biochem Mol Toxicol.
37:e233812023. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Shi Z, Li Z, Jin B, Ye W, Wang L, Zhang S,
Zheng J, Lin Z, Chen B, Liu F, et al: Loss of LncRNA DUXAP8
synergistically enhanced sorafenib induced ferroptosis in
hepatocellular carcinoma via SLC7A11 de-palmitoylation. Clin Transl
Med. 13:e13002023. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Zhang B, Bao W, Zhang S, Chen B, Zhou X,
Zhao J, Shi Z, Zhang T, Chen Z, Wang L, et al: LncRNA HEPFAL
accelerates ferroptosis in hepatocellular carcinoma by regulating
SLC7A11 ubiquitination. Cell Death Dis. 13:7342022. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Wang J, Jia Q, Jiang S, Lu W and Ning H:
POU6F1 promotes ferroptosis by increasing lncRNA-CASC2
transcription to regulate SOCS2/SLC7A11 signaling in gastric
cancer. Cell Biol Toxicol. 40:32024. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Lin Z, Song J, Gao Y, Huang S, Dou R,
Zhong P, Huang G, Han L, Zheng J, Zhang X, et al: Hypoxia-induced
HIF-1α/lncRNA-PMAN inhibits ferroptosis by promoting the
cytoplasmic translocation of ELAVL1 in peritoneal dissemination
from gastric cancer. Redox Biol. 52:1023122022. View Article : Google Scholar
|
|
146
|
Yang R, Wan J, Ma L, Zhou F, Yang Z, Li Z,
Zhang M and Ming L: TMEM44-AS1 promotes esophageal squamous cell
carcinoma progression by regulating the IGF2BP2-GPX4 axis in
modulating ferroptosis. Cell Death Discov. 9:4312023. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Lei S, Cao W, Zeng Z, Zhang Z, Jin B, Tian
Q, Wu Y, Zhang T, Li D, Hu C, et al: JUND/linc00976 promotes
cholangiocarcinoma progression and metastasis, inhibits ferroptosis
by regulating the miR-3202/GPX4 axis. Cell Death Dis. 13:9672022.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Yuan J, Lv T, Yang J, Wu Z, Yan L, Yang J
and Shi Y: HDLBP-stabilized lncFAL inhibits ferroptosis
vulnerability by diminishing Trim69-dependent FSP1 degradation in
hepatocellular carcinoma. Redox Biol. 58:1025462022. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Han Y, Gao X, Wu N, Jin Y, Zhou H, Wang W,
Liu H, Chu Y, Cao J, Jiang M, et al: Long noncoding RNA LINC00239
inhibits ferroptosis in colorectal cancer by binding to Keap1 to
stabilize Nrf2. Cell Death Dis. 13:7422022. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Gao Y, Tong M, Wong TL, Ng KY, Xie YN,
Wang Z, Yu H, Loh JJ, Li M and Ma S: Long noncoding RNA
URB1-antisense RNA 1 (AS1) suppresses sorafenib-induced ferroptosis
in hepatocellular carcinoma by driving ferritin phase separation.
ACS Nano. 17:22240–22258. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Zhang Y, Luo M, Cui X, O'Connell D and
Yang Y: Long noncoding RNA NEAT1 promotes ferroptosis by modulating
the miR-362-3p/MIOX axis as a ceRNA. Cell Death Differ.
29:1850–1863. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Guan L, Wang F, Wang M, Han S, Cui Z, Xi
S, Xu H and Li S: Downregulation of HULC induces ferroptosis in
hepatocellular carcinoma via targeting of the miR-3200-5p/ATF4
axis. Oxid Med Cell Longev. 2022:96130952022. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Wang H, Klein MG, Zou H, Lane W, Snell G,
Levin I, Li K and Sang BC: Crystal structure of human
stearoyl-coenzyme A desaturase in complex with substrate. Nat
Struct Mol Biol. 22:581–585. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Li J, Condello S, Thomes-Pepin J, Ma X,
Xia Y, Hurley TD, Matei D and Cheng JX: Lipid desaturation is a
metabolic marker and therapeutic target of ovarian cancer stem
cells. Cell Stem Cell. 20:303–314.e5. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Sen U, Coleman C and Sen T: Stearoyl
coenzyme A desaturase-1: Multitasker in cancer, metabolism, and
ferroptosis. Trends Cancer. 9:480–489. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Tesfay L, Paul BT, Konstorum A, Deng Z,
Cox AO, Lee J, Furdui CM, Hegde P, Torti FM and Torti SV:
Stearoyl-CoA desaturase 1 protects ovarian cancer cells from
ferroptotic cell death. Cancer Res. 79:5355–5366. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Luo Y, Huang S, Wei J, Zhou H, Wang W,
Yang J, Deng Q, Wang H and Fu Z: Long noncoding RNA LINC01606
protects colon cancer cells from ferroptotic cell death and
promotes stemness by SCD1-Wnt/β-catenin-TFE3 feedback loop
signalling. Clin Transl Med. 12:e7522022. View Article : Google Scholar
|
|
158
|
Yang H, Hu Y, Weng M, Liu X, Wan P, Hu Y,
Ma M, Zhang Y, Xia H and Lv K: Hypoxia inducible lncRNA-CBSLR
modulates ferroptosis through m6A-YTHDF2-dependent modulation of
CBS in gastric cancer. J Adv Res. 37:91–106. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Qu X, Liu B, Wang L, Liu L, Zhao W, Liu C,
Ding J, Zhao S, Xu B, Yu H, et al: Loss of cancer-associated
fibroblast-derived exosomal DACT3-AS1 promotes malignant
transformation and Ferroptosis-mediated oxaliplatin resistance in
gastric cancer. Drug Resist Updat. 68:1009362023. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Kristensen LS, Hansen TB, Venø MT and
Kjems J: Circular RNAs in cancer: Opportunities and challenges in
the field. Oncogene. 37:555–565. 2018. View Article : Google Scholar :
|
|
161
|
Zheng Q, Bao C, Guo W, Li S, Chen J, Chen
B, Luo Y, Lyu D, Li Y, Shi G, et al: Circular RNA profiling reveals
an abundant circHIPK3 that regulates cell growth by sponging
multiple miRNAs. Nat Commun. 7:112152016. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Wang Y, Chen H and Wei X: Circ_0007142
downregulates miR-874-3p-mediated GDPD5 on colorectal cancer cells.
Eur J Clin Invest. 51:e135412021. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Gao X and Wang XL: Dexmedetomidine
promotes ferroptotic cell death in gastric cancer via
hsa_circ_0008035/miR-302a/E2F7 axis. Kaohsiung J Med Sci.
39:390–403. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Yao W, Wang J, Meng F, Zhu Z, Jia X, Xu L,
Zhang Q and Wei L: Circular RNA CircPVT1 Inhibits 5-Fluorouracil
chemosensitivity by regulating ferroptosis through MiR-30a-5p/FZD3
axis in esophageal cancer cells. Front Oncol. 11:7809382021.
View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Zhai H, Zhong S, Wu R, Mo Z, Zheng S, Xue
J, Meng H, Liu M, Chen X, Zhang G, et al: Suppressing
circIDE/miR-19b-3p/RBMS1 axis exhibits promoting-tumour activity
through upregulating GPX4 to diminish ferroptosis in hepatocellular
carcinoma. Epigenetics. 18:21924382023. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Xu Q, Zhou L, Yang G, Meng F, Wan Y, Wang
L and Zhang L: CircIL4R facilitates the tumorigenesis and inhibits
ferroptosis in hepatocellular carcinoma by regulating the
miR-541-3p/GPX4 axis. Cell Biol Int. 44:2344–2356. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Liu Y and Li J: Circular RNA 0016142
knockdown induces ferroptosis in hepatocellular carcinoma cells via
modulation of the MicroRNA-188-3p/Glutathione peroxidase 4 axis.
Biochem Genet. 62:333–351. 2024. View Article : Google Scholar
|
|
168
|
Tan YR, Jiang BH, Feng WJ, He ZL, Jiang
YL, Xun Y, Wu XP, Li YH and Zhu HB: Circ0060467 sponges miR-6805 to
promote hepatocellular carcinoma progression through regulating
AIFM2 and GPX4 expression. Aging (Albany NY). 16:1796–1807. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Lyu N, Zeng Y, Kong Y, Chen Q, Deng H, Ou
S, Bai Y, Tang H, Wang X and Zhao M: Ferroptosis is involved in the
progression of hepatocellular carcinoma through the
circ0097009/miR-1261/SLC7A11 axis. Ann Transl Med. 9:6752021.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Li Q, Li K, Guo Q and Yang T: CircRNA
circSTIL inhibits ferroptosis in colorectal cancer via
miR-431/SLC7A11 axis. Environ Toxicol. 38:981–989. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Liu J, Yang H, Deng J, Jiang R, Meng E and
Wu H: CircRPPH1 promotes the stemness of gastric cancer cells by
targeting miR-375/SLC7A11 axis. Environ Toxicol. 38:115–125. 2023.
View Article : Google Scholar
|
|
172
|
Wang H, Breadner DA, Deng K and Niu J:
CircRHOT1 restricts gastric cancer cell ferroptosis by
epigenetically regulating GPX4. J Gastrointest Oncol. 14:1715–1725.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Majumder M, Chakraborty P, Mohan S,
Mehrotra S and Palanisamy V: HuR as a molecular target for cancer
therapeutics and immune-related disorders. Adv Drug Deliv Rev.
188:1144422022. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Long F, Zhong C, Long Q, Zhu K, Wang J, Yu
Y, Xie C and Hu G: Circular RNA RHBDD1 regulates tumorigenicity and
ferroptosis in colorectal cancer by mediating the ELAVL1/SCD mRNA
interaction. Cancer Gene Ther. 31:237–249. 2024. View Article : Google Scholar
|
|
175
|
Zhou P, Wu Z, Zhang Q, Wang L, Zhang W and
Han X: A novel link between circPDE3B and ferroptosis in esophageal
squamous cell carcinoma progression. Genomics. 116:1107612024.
View Article : Google Scholar
|
|
176
|
Zhang X, Sui S, Wang L, Li H, Zhang L, Xu
S and Zheng X: Inhibition of tumor propellant glutathione
peroxidase 4 induces ferroptosis in cancer cells and enhances
anticancer effect of cisplatin. J Cell Physiol. 235:3425–3437.
2020. View Article : Google Scholar
|
|
177
|
Katsha A, Belkhiri A, Goff L and El-Rifai
W: Aurora kinase A in gastrointestinal cancers: Time to target. Mol
Cancer. 14:1062015. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Du R, Huang C, Liu K, Li X and Dong Z:
Targeting AURKA in cancer: Molecular mechanisms and opportunities
for cancer therapy. Mol Cancer. 20:152021. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Gomaa A, Peng D, Chen Z, Soutto M,
Abouelezz K, Corvalan A and El-Rifai W: Epigenetic regulation of
AURKA by miR-4715-3p in upper gastrointestinal cancers. Sci Rep.
9:169702019. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Prasad S, Gupta SC and Tyagi AK: Reactive
oxygen species (ROS) and cancer: Role of antioxidative
nutraceuticals. Cancer Lett. 387:95–105. 2017. View Article : Google Scholar
|
|
181
|
Zhang X, Ma L and Wang J: Cross-regulation
between redox and epigenetic systems in tumorigenesis: Molecular
mechanisms and clinical applications. Antioxid Redox Signal.
39:445–471. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Kang KA, Zhang R, Kim GY, Bae SC and Hyun
JW: Epigenetic changes induced by oxidative stress in colorectal
cancer cells: methylation of tumor suppressor RUNX3. Tumour Biol.
33:403–412. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Zhang R, Kang KA, Kim KC, Na SY, Chang WY,
Kim GY, Kim HS and Hyun JW: Oxidative stress causes epigenetic
alteration of CDX1 expression in colorectal cancer cells. Gene.
524:214–219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Lim SO, Gu JM, Kim MS, Kim HS, Park YN,
Park CK, Cho JW, Park YM and Jung G: Epigenetic changes induced by
reactive oxygen species in hepatocellular carcinoma: Methylation of
the E-cadherin promoter. Gastroenterology. 135:2128–2140. e1–e8.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Liao P, Wang W, Wang W, Kryczek I, Li X,
Bian Y, Sell A, Wei S, Grove S, Johnson JK, et al: CD8+
T cells and fatty acids orchestrate tumor ferroptosis and immunity
via ACSL4. Cancer Cell. 40:365–378.e366. 2022. View Article : Google Scholar
|
|
186
|
Wang W, Green M, Choi JE, Gijón M, Kennedy
PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, et al:
CD8+ T cells regulate tumour ferroptosis during cancer
immunotherapy. Nature. 569:270–274. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Sahai E, Astsaturov I, Cukierman E,
DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR,
Hunter T, et al: A framework for advancing our understanding of
cancerassociated fibroblasts. Nat Rev Cancer. 20:174–186. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Jiang F, Jia K, Chen Y, Ji C, Chong X, Li
Z, Zhao F, Bai Y, Ge S, Gao J, et al: ANO1-mediated inhibition of
cancer ferroptosis confers immunotherapeutic resistance through
recruiting cancer-associated fibroblasts. Adv Sci (Weinh).
10:e23008812023. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Leone RD and Powell JD: Metabolism of
immune cells in cancer. Nat Rev Cancer. 20:516–531. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Angelin A, Gil-de-Gómez L, Dahiya S, Jiao
J, Guo L, Levine MH, Wang Z, Quinn WJ III, Kopinski PK, Wang L, et
al: Foxp3 reprograms T cell metabolism to function in low-glucose,
high-lactate environments. Cell Metab. 25:1282–1293.e7. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Zhao Y, Li M, Yao X, Fei Y, Lin Z, Li Z,
Cai K, Zhao Y and Luo Z: HCAR1/MCT1 regulates tumor ferroptosis
through the lactate-mediated AMPK-SCD1 activity and its therapeutic
implications. Cell Rep. 33:1084872020. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Yang Z, Su W, Wei X, Qu S, Zhao D, Zhou J,
Wang Y, Guan Q, Qin C, Xiang J, et al: HIF-1α drives resistance to
ferroptosis in solid tumors by promoting lactate production and
activating SLC1A1. Cell Rep. 42:1129452023. View Article : Google Scholar
|
|
193
|
Babar Q, Saeed A, Tabish TA, Pricl S,
Townley H and Thorat N: Novel epigenetic therapeutic strategies and
targets in cancer. Biochim Biophys Acta Mol Basis Dis.
1868:1665522022. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Fan F, Liu P, Bao R, Chen J, Zhou M, Mo Z,
Ma Y, Liu H, Zhou Y, Cai X, et al: A dual PI3K/HDAC inhibitor
induces immunogenic ferroptosis to potentiate cancer immune
checkpoint therapy. Cancer Res. 81:6233–6245. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Yang Z, Su W, Zhang Q, Niu L, Feng B,
Zhang Y, Huang F, He J, Zhou Q, Zhou X, et al: Lactylation of HDAC1
confers resistance to ferroptosis in colorectal cancer. Adv Sci
(Weinh). 12:e24088452025. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Jenke R, Oliinyk D, Zenz T, Körfer J,
Schäker-Hübner L, Hansen FK, Lordick F, Meier-Rosar F, Aigner A and
Büch T: HDAC inhibitors activate lipid peroxidation and ferroptosis
in gastric cancer. Biochem Pharmacol. 225:1162572024. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Bitzer M, Horger M, Giannini EG, Ganten
TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege
H, et al: Resminostat plus sorafenib as second-line therapy of
advanced hepatocellular carcinoma-The SHELTER study. J Hepatol.
65:280–288. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Baretti M, Danilova L, Durham JN, Betts
CB, Cope L, Sidiropoulos DN, Tandurella JA, Charmsaz S, Gross N,
Hernandez A, et al: Entinostat in combination with nivolumab in
metastatic pancreatic ductal adenocarcinoma: A phase 2 clinical
trial. Nat Commun. 15:98012024. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Olsen EA, Kim YH, Kuzel TM, Pacheco TR,
Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM and
Duvic M: Phase IIb multicenter trial of vorinostat in patients with
persistent, progressive, or treatment refractory cutaneous T-cell
lymphoma. J Clin Oncol. 25:3109–3115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Piekarz RL, Frye AR, Wright JJ, Steinberg
SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T and Bates SE: Cardiac
studies in patients treated with depsipeptide, FK228, in a phase II
trial for T-cell lymphoma. Clin Cancer Res. 12:3762–3773. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Duvic M, Talpur R, Ni X, Zhang C, Hazarika
P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, et al: Phase
2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA)
for refractory cutaneous T-cell lymphoma (CTCL). Blood. 109:31–39.
2007. View Article : Google Scholar
|
|
202
|
Whittaker SJ, Demierre MF, Kim EJ, Rook
AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC,
et al: Final results from a multicenter, international, pivotal
study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin
Oncol. 28:4485–4491. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
O'Connor OA, Heaney ML, Schwartz L,
Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C,
Portlock C, Horwitz S, et al: Clinical experience with intravenous
and oral formulations of the novel histone deacetylase inhibitor
suberoylanilide hydroxamic acid in patients with advanced
hematologic malignancies. J Clin Oncol. 24:166–173. 2006.
View Article : Google Scholar
|
|
204
|
Chen S, Zheng Y, Liang B, Yin Y, Yao J,
Wang Q, Liu Y and Neamati N: The application of PROTAC in HDAC. Eur
J Med Chem. 260:1157462023. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Cheng B, Pan W, Xiao Y, Ding Z, Zhou Y,
Fei X, Liu J, Su Z, Peng X and Chen J: HDAC-targeting epigenetic
modulators for cancer immunotherapy. Eur J Med Chem.
265:1161292024. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Lai Y, Han X, Xie B, Xu Y, Yang Z, Wang D,
Li W, Xie Y, Song W, Zhang X, et al: EZH2 suppresses ferroptosis in
hepatocellular carcinoma and reduces sorafenib sensitivity through
epigenetic regulation of TFR2. Cancer Sci. 115:2220–2234. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Yan H, Parsons DW, Jin G, McLendon R,
Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ,
et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med.
360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Mardis ER, Ding L, Dooling DJ, Larson DE,
McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath
SD, et al: Recurring mutations found by sequencing an acute myeloid
leukemia genome. N Engl J Med. 361:1058–1066. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Amary MF, Bacsi K, Maggiani F, Damato S,
Halai D, Berisha F, Pollock R, O'Donnell P, Grigoriadis A, Diss T,
et al: IDH1 and IDH2 mutations are frequent events in central
chondrosarcoma and central and periosteal chondromas but not in
other mesenchymal tumours. J Pathol. 224:334–343. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Dang L, White DW, Gross S, Bennett BD,
Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et
al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Nature. 462:739–744. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim
SH, Ito S, Yang C, Wang P, Xiao MT, et al: Oncometabolite
2-hydroxyglutarate is a competitive inhibitor of
α-ketoglutarate-dependent dioxygenases. Cancer Cell. 19:17–30.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Turcan S, Rohle D, Goenka A, Walsh LA,
Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, et al: IDH1
mutation is sufficient to establish the glioma hypermethylator
phenotype. Nature. 483:479–483. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Figueroa ME, Abdel-Wahab O, Lu C, Ward PS,
Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et
al: Leukemic IDH1 and IDH2 mutations result in a hypermethylation
phenotype, disrupt TET2 function, and impair hematopoietic
differentiation. Cancer Cell. 18:553–567. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Zarei M, Hajihassani O, Hue JJ, Loftus AW,
Graor HJ, Nakazzi F, Naji P, Boutros CS, Uppin V, Vaziri-Gohar A,
et al: IDH1 inhibition potentiates chemotherapy efficacy in
pancreatic cancer. Cancer Res. 84:3072–3085. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Zhu AX, Macarulla T, Javle MM, Kelley RK,
Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater
JA, et al: Final overall survival efficacy results of ivosidenib
for patients with advanced cholangiocarcinoma with IDH1 mutation:
The phase 3 randomized clinical ClarIDHy trial. JAMA Oncol.
7:1669–1677. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Chen W, Yang W, Zhang C, Liu T, Zhu J,
Wang H, Li T, Jin A, Ding L, Xian J, et al: Modulation of the p38
MAPK pathway by anisomycin promotes ferroptosis of hepatocellular
carcinoma through phosphorylation of H3S10. Oxid Med Cell Longev.
2022:69864452022. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Sun X, Ou Z, Xie M, Kang R, Fan Y, Niu X,
Wang H, Cao L and Tang D: HSPB1 as a novel regulator of ferroptotic
cancer cell death. Oncogene. 34:5617–5625. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Sun J, Liu Q, Jiang Y, Cai Z, Liu H and
Zuo H: Engineered small extracellular vesicles loaded with
miR-654-5p promote ferroptosis by targeting HSPB1 to alleviate
sorafenib resistance in hepatocellular carcinoma. Cell Death
Discov. 9:3622023. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar
|
|
220
|
Dixon SJ, Patel DN, Welsch M, Skouta R,
Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS,
et al: Pharmacological inhibition of cystine-glutamate exchange
induces endoplasmic reticulum stress and ferroptosis. Elife.
3:e025232014. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Shi CJ, Pang FX, Lei YH, Deng LQ, Pan FZ,
Liang ZQ, Xie T, Wu XL, Wang YY, Xian YF, et al: 5-methylcytosine
methylation of MALAT1 promotes resistance to sorafenib in
hepatocellular carcinoma through ELAVL1/SLC7A11-mediated
ferroptosis. Drug Resist Updat. 78:1011812025. View Article : Google Scholar
|
|
222
|
Terekhanova NV, Karpova A, Liang WW,
Strzalkowski A, Chen S, Li Y, Southard-Smith AN, Iglesia MD, Wendl
MC, Jayasinghe RG, et al: Epigenetic regulation during cancer
transitions across 11 tumour types. Nature. 623:432–441. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Rotem A, Ram O, Shoresh N, Sperling RA,
Goren A, Weitz DA and Bernstein BE: Single-cell ChIP-seq reveals
cell subpopulations defined by chromatin state. Nat Biotechnol.
33:1165–1172. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Wang SW, Gao C, Zheng YM, Yi L, Lu JC,
Huang XY, Cai JB, Zhang PF, Cui YH and Ke AW: Current applications
and future perspective of CRISPR/Cas9 gene editing in cancer. Mol
Cancer. 21:572022. View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Pun FW, Ozerov IV and Zhavoronkov A:
AI-powered therapeutic target discovery. Trends Pharmacol Sci.
44:561–572. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Pratt D, Sahm F and Aldape K: DNA
methylation profiling as a model for discovery and precision
diagnostics in neuro-oncology. Neuro Oncol. 23(23 Suppl 5):
S16–S29. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Dai Q, Ye C, Irkliyenko I, Wang Y, Sun HL,
Gao Y, Liu Y, Beadell A, Perea J, Goel A, et al: Ultrafast
bisulfite sequencing detection of 5-methylcytosine in DNA and RNA.
Nat Biotechnol. 42:1559–1570. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Lone SN, Nisar S, Masoodi T, Singh M,
Rizwan A, Hashem S, El-Rifai W, Bedognetti D, Batra SK, Haris M, et
al: Liquid biopsy: A step closer to transform diagnosis, prognosis
and future of cancer treatments. Mol Cancer. 21:792022. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Zhao J, Cui X, Zhan Q, Zhang K, Su D, Yang
S, Hong B, Wang Q, Ju J, Cheng C, et al: CRISPR-Cas9 library
screening combined with an exosome-targeted delivery system
addresses tumorigenesis/TMZ resistance in the mesenchymal subtype
of glioblastoma. Theranostics. 14:2835–2855. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Gulati GS, D'Silva JP, Liu Y, Wang L and
Newman AM: Profiling cell identity and tissue architecture with
single-cell and spatial transcriptomics. Nat Rev Mol Cell Biol.
26:11–31. 2025. View Article : Google Scholar
|
